Meeting
2017 ASCO Annual Meeting
A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers.
Authors
Joline Si Jing Lim
Royal Marsden Hospital, Sutton, United Kingdom
Joline Si Jing Lim , Uzma Saddia Asghar , Nikolaos Diamantis , Sarah Emily Ward , Mona Parmar , Beth Purchase , Florence I. Raynaud , Karen E Swales , Sarah Hrebien , Emma Hall , Holly Tovey , Hannah Bye , Juanita Suzanne Lopez , Alison Joanne Turner , Johann S. De Bono , Udai Banerji , Timothy Anthony Yap , Nicholas C. Turner , Paula Proszek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02389842
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2573)
DOI
10.1200/JCO.2017.35.15_suppl.2573
Abstract #
2573
Poster Bd #
65
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.
First Author: Juanita Suzanne Lopez
Poster
2019 ASCO Annual Meeting
PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.
First Author: Javier Pascual
Poster
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz
Poster
2018 ASCO Annual Meeting
A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis.
First Author: Romualdo Barroso-Sousa